Showing 811-820 of 9757 results for "".
Primary Care Providers as Allies in Dermatology
https://practicaldermatology.com/topics/practice-management/primary-care-providers-as-allies-in-dermatology/21117/In light of a dermatology workforce shortage, PCPs see a majority of skin-related cases. Dermatologists can work with them to improve patient care.What If It’s Not Atopic Dermatitis?
https://practicaldermatology.com/topics/infections-infectious-disease/what-if-its-not-atopic-dermatitis/23812/A photo-assisted guide to differential diagnosis.Biosimilar Medicines in Dermatology: Key Aspects
https://practicaldermatology.com/topics/psoriasis/biosimilar-medicines-in-dermatology-key-aspects/22929/After the recent enactment of a specific approval pathway for biosimilars and publication of the first draft guidelines on biosimilar product development by the FDA, biosimilars are expected to be available in the US soon.Update on Isotretinoin, Depression, and Suicide: Appropriate Monitoring is Key
https://practicaldermatology.com/topics/general-topics/update-on-isotretinoin-depression-and-suicide-appropriate-monitoring-is-key/21859/Data have failed to show a direct relationship between isotretinoin use and depression or suicide, but the cumulative evidence suggests patients with severe acne require careful monitoring.Ortho Dermatologics NDA, J&J Innovation, Consumer Credit Insights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-ortho-dermatologics-nda-j-j-innovation-consumer-credit-insights/18395/Two-thirds of prospective patients say they would be more likely to book a procedure if they were aware of financing options. More than three-quarters of prospective patients are unaware of financing options, according to a recent survey by Zalea. In conjunction with Johnson & Johnson Consumer,BPO and Alternative Acne Options
https://practicaldermatology.com/issues/july-2025/bpo-alternative-acne-options/36505/Acne treatments have been in the spotlight more than usual recently, as Valisure and the US Food and Drug Administration (FDA) have examined benzoyl peroxide (BPO) products for benzene contamination. At the same time, innovative new options are becoming available. Practical Dermatology spoke to DianEfficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Tri-State Analysis of the Distribution of Southeastern Dermatologists and Dermatology Residency Graduates Among Rural and Urban Areas
https://practicaldermatology.com/issues/november-2024/tri-state-analysis-distribution-southeastern-dermatologists-and-dermatology-residency-graduates-among-rural-and-urban-areas/29799/The nation faces a shortage of dermatologists, and this issue is most prevalent in rural areas. The objective of this study is to analyze the distribution of dermatologists and graduates of dermatology residency programs across the southeastern region and the factors that influence this distributionEfficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.